Application of obeticholic acid in preparation of medicine for treating tamoxifen hepatotoxicity
Through the application of obebicholic acid, the problem of hepatotoxicity of tamoxifen was solved. By reducing hepatocellular edema, enhancing antioxidant stress ability and improving enterohepatic FXR signal disorder, the clinical management of hepatotoxicity of tamoxifen is provided. Effective intervention measures have improved the efficacy of breast cancer treatment.
Patent Information
- Application Number
- CN202411147945.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-20
- Publication Date
- 2024-11-08
AI Technical Summary
Tamoxifen may lead to drug-induced liver damage and hepatotoxicity in endocrine treatment of breast cancer, and there is no effective intervention measure, which will affect the treatment effect.
Using obeiccholic acid (OCA) or its pharmaceutically acceptable salt, the drug is administered through gavage to reduce hepatocyte edema, reduce the content of oxidized glutathione, increase the ratio of reducing glutathione/GSSG, and enhance the anti-antibody Oxidative stress capacity and improve enterohepatic FXR signal disorder.
It significantly reduces the hepatotoxicity of tamoxifen, restores hepatocyte damage, improves liver function, reduces serum ALP levels, improves abnormal conduction of enterohepatic FXR signal, and provides clinical management intervention solutions.
Smart Images

Figure BDA0005003206020000103 
Figure BDA0005003206020000111 
Figure HDA0005003206080000011
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biomedical technology, and in particular to the use of obeticholic acid in preparing a drug for alleviating or treating tamoxifen hepatotoxicity. Background Art
[0002] Endocrine therapy is the first-line treatment for breast cancer patients. Tamoxifen (TAM) is an oral estrogen receptor modulator and the first-line drug of choice for endocrine therapy of breast cancer patients, with a treatment cycle of up to 5 to 10 years. However, TAM may induce drug-induced liver injury in patients during clinical use. The incidence of drug-induced fatty liver in patients after endocrine therapy with TAM is as high as over 40%, and some patients even develop hepatitis and cirrhosis. Related animal experiments have also confirmed that TAM can induce oxidative stress-induced liver injury. In a long-term toxicity test, researchers found that TAM can even induce hepatocellular carcinoma in a rat model. The high incidence of TAM hepatotoxicity reduces patients' tolerance to it, forcing clinical medication to be reduced or even discontinued, seriously affecting the clinical efficacy of TAM in the treatment of breast cancer.
[0003] The intestinal flora is a key driver of drug-induced liver injury. The liver, intestines and their flora are closely connected in anatomy and function, integrating endogenous and exogenous signals to form an "intestinal-liver" axis, and participate in maintaining the normal function of liver and intestine. Bile acid is a host-intestinal flora co-metabolite, composed of primary bile acids and secondary bile acids. Primary bile acids are synthesized by the liver and mainly react with taurine or glycine to form conjugated primary bile acids, increasing their solubility in bile. They then enter the intestine with bile and can be catalyzed and metabolized by the intestinal flora through a series of enzymatic reactions to produce secondary bile acids. In the host-intestinal flora interaction network, bile acids undergo multiple links such as synthesis, metabolism, reabsorption and distribution, and act as signal molecules of the intestinal-liver axis through the enterohepatic circulation, participating in the regulation of metabolism and immune responses in the intestine and liver, and synergistically shaping the composition and function of the intestinal flora. Farnesoid X Receptor (FXR) is a key receptor for bile acid binding, negatively feedback-regulating bile acid synthesis, and abnormal bile acid profiles can lead to intestinal hepatic FXR signaling disorders. Many studies have shown that "gut flora-bile acid-FXR" signaling plays a very important role in regulating liver metabolism, shaping intestinal flora, and maintaining intestinal function. Obeticholic acid (OCA) is a FXR agonist that can improve intestinal hepatic FXR signaling and is used to treat cholestatic liver disease, primary biliary cirrhosis, and non-alcoholic fatty liver disease. However, no studies have shown that obeticholic acid can be used for the intervention and treatment of TAM hepatotoxicity.
[0004] The present invention verifies the therapeutic potential of obeticholic acid in TAM hepatotoxicity and provides an intervention plan for the clinical management of TAM hepatotoxicity. Summary of the invention
[0005] The present invention aims to solve at least one of the technical problems existing in the prior art. To this end, the present invention provides the use of obeticholic acid and / or its pharmaceutically acceptable salt in the preparation of a drug for alleviating and / or treating tamoxifen hepatotoxicity. The present invention finds that obeticholic acid (OCA) can restore the damage of tamoxifen (TAM) hepatotoxicity to hepatocytes, reduce hepatocyte edema, and can also significantly reduce the GSSG (oxidized glutathione) content of damaged liver, increase the liver GSH (reduced glutathione) / GSSG content ratio, enhance the antioxidant stress capacity of damaged liver, and reduce serum ALP levels, reduce TAM hepatotoxicity, in addition, the present invention also finds that OCA treatment can improve the abnormal conduction of enterohepatic FXR signals caused by tamoxifen, so OCA has the potential to become a therapeutic strategy for the clinical management of TAM hepatotoxicity. Provide an intervention plan for the clinical management of TAM hepatotoxicity.
[0006] The present invention also provides a medicine for combined treatment of breast cancer and tamoxifen hepatotoxicity.
[0007] The first aspect of the present invention provides the use of obeticholic acid and / or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating tamoxifen hepatotoxicity.
[0008] According to a specific embodiment of the present invention, the present invention finds that a certain dose of OCA gavage treatment of TAM hepatotoxicity model mice can improve TAM-induced hepatotoxicity; specifically, OCA can reduce the degree of damage to mouse liver cells, reduce hepatocellular edema, and significantly reduce the serum ALP level of TAM hepatotoxic mice, enhance mouse liver function, and OCA can significantly reduce the content of GSSG in mouse liver, while increasing the liver GSH / GSSG ratio, significantly improving the liver function damaged by TAM hepatotoxicity. In addition, the present invention also finds that OCA can inhibit the high transcription state of liver bile acid synthase in TAM hepatotoxic mice and reverse the abnormal conduction of enterohepatic FXR signals induced by TAM. Therefore, the present invention provides the use of OCA in the preparation of drugs for alleviating or treating TAM hepatotoxicity, which has a good application prospect in clinical endocrine treatment of breast cancer.
[0009] According to some embodiments of the invention, the treatment comprises alleviating or restoring tamoxifen-induced liver toxicity.
[0010] According to some embodiments of the present invention, the tamoxifen hepatotoxicity includes drug-induced liver injury caused by the use of tamoxifen endocrine therapy for breast cancer.
[0011] According to some embodiments of the present invention, the functions of the drug specifically include at least one of reducing hepatocyte edema, enhancing the liver's ability to resist oxidative stress, reducing serum ALP levels, and improving tamoxifen-induced enterohepatic FXR signaling disorder.
[0012] According to some embodiments of the present invention, the reducing hepatocyte edema is reducing hepatocyte edema in patients with tamoxifen hepatotoxicity.
[0013] According to some embodiments of the present invention, the enhancing the anti-oxidative stress capacity of the liver is enhancing the anti-oxidative stress capacity of the liver of patients with tamoxifen hepatotoxicity.
[0014] According to some embodiments of the present invention, enhancing the liver's ability to resist oxidative stress comprises reducing the liver's GSSG content and / or increasing the liver's GSH / GSSG content ratio.
[0015] According to some embodiments of the present invention, the lowering of serum ALP levels is lowering of serum ALP levels in patients with tamoxifen hepatotoxicity.
[0016] According to some embodiments of the invention, the improving tamoxifen-induced enterohepatic FXR signaling disorder comprises reducing the expression of hepatic bile acid synthase.
[0017] According to some embodiments of the invention, the hepatic bile acid synthase comprises at least one of CYP7A1, CYP8B1, CYP27A1 or CYP7B1.
[0018] According to some embodiments of the invention, the liver bile acid synthase includes CYP7A1, CYP8B1, CYP27A1 and CYP7B1.
[0019] According to some embodiments of the invention, the hepatic bile acid synthase comprises CYP7A1, CYP27A1 and CYP7B1.
[0020] According to some embodiments of the present invention, the dosage of obeticholic acid and / or a pharmaceutically acceptable salt thereof in the medicament is 5 to 40 mg / kg / d.
[0021] According to some embodiments of the present invention, the dosage of obeticholic acid and / or a pharmaceutically acceptable salt thereof in the medicament is 8 to 30 mg / kg / d.
[0022] According to some embodiments of the present invention, the dosage of obeticholic acid and / or a pharmaceutically acceptable salt thereof in the medicament is 10 to 20 mg / kg / d.
[0023] According to some embodiments of the present invention, the drug is administered for 2 to 6 weeks.
[0024] According to some embodiments of the present invention, the drug is administered for 3 to 5 weeks.
[0025] According to some embodiments of the present invention, the dosage form of the drug is tablets, capsules, granules, pills, oral liquids, dry suspensions, dry extracts or injections.
[0026] According to some embodiments of the present invention, the dosage form of the drug is an oral solution.
[0027] According to some embodiments of the present invention, the drug further comprises a pharmaceutically acceptable excipient.
[0028] According to some embodiments of the present invention, the pharmaceutically acceptable excipients include at least one of a diluent, an excipient, a filler, a binder, a disintegrant, an absorption enhancer, a surfactant, an adsorption carrier, a lubricant, a sweetener and a flavoring agent.
[0029] According to some embodiments of the invention, the excipient comprises water.
[0030] According to some embodiments of the present invention, the filler comprises at least one of starch and sucrose.
[0031] According to some embodiments of the present invention, the binder comprises at least one of a cellulose derivative, alginate, gelatin, and polyvinyl pyrrolidone.
[0032] According to some embodiments of the invention, the humectant comprises glycerol.
[0033] According to some embodiments of the invention, the disintegrant comprises at least one of agar, calcium carbonate, and sodium bicarbonate.
[0034] According to some embodiments of the invention, the absorption enhancer comprises a quaternary ammonium compound.
[0035] According to some embodiments of the invention, the surfactant comprises cetyl alcohol.
[0036] According to some embodiments of the present invention, the adsorption carrier includes at least one of kaolin and bentonite.
[0037] According to some embodiments of the present invention, the lubricant comprises at least one of talc, calcium stearate, magnesium stearate, and polyethylene glycol.
[0038] According to some embodiments of the present invention, the dosage form of the drug is any conventional dosage form in the art.
[0039] According to some embodiments of the present invention, the administration method of the drug can be a conventional administration method in the art, including but not limited to intragastric administration.
[0040] A second aspect of the present invention provides a drug for the combined treatment of breast cancer and tamoxifen hepatotoxicity, wherein the active substances of the drug include tamoxifen and obeticholic acid.
[0041] According to some embodiments of the present invention, the dosage of tamoxifen in the drug is 100-300 mg / kg / d, and the dosage of obeticholic acid in the drug is 5-40 mg / kg / d.
[0042] According to some embodiments of the present invention, the dosage of tamoxifen in the drug is 150-250 mg / kg / d, and the dosage of obeticholic acid in the drug is 8-30 mg / kg / d.
[0043] According to some embodiments of the present invention, the dosage of tamoxifen in the drug is 150-250 mg / kg / d, and the dosage of obeticholic acid in the drug is 10-20 mg / kg / d.
[0044] According to some embodiments of the present invention, the administration method of the drug can be a conventional administration method in the art, including but not limited to intragastric administration.
[0045] The drug for combined treatment of breast cancer and tamoxifen hepatotoxicity proposed in the present invention can not only achieve endocrine treatment of breast cancer, but also alleviate and treat drug-induced liver damage caused by tamoxifen hepatotoxicity after endocrine treatment, improve patients' tolerance to tamoxifen, avoid reduction in tamoxifen dosage, and thus improve the therapeutic effect on breast cancer.
[0046] General terms:
[0047] The term "pharmaceutically acceptable" as used herein refers to molecular entities and compositions that do not produce adverse reactions, allergic reactions or other untoward reactions when administered to animals or humans.
[0048] The "pharmaceutically acceptable salts" mentioned in the present invention include base addition salts and acid addition salts.
[0049] Pharmaceutically acceptable base addition salts can be formed with metals or amines (e.g., alkali metals and alkaline earth metals or organic amines). Pharmaceutically acceptable salts of compounds can also be prepared with pharmaceutically acceptable cations. Suitable pharmaceutically acceptable cations are well known to those skilled in the art and include alkali metal cations, alkaline earth metal cations, ammonium cations, and quaternary ammonium cations. Carbonates or bicarbonates are also possible. Metals used as cations are sodium, potassium, magnesium, ammonium, calcium, or ferric iron, etc. Suitable amines include isopropylamine, trimethylamine, histidine, N,N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, dicyclohexylamine, ethylenediamine, N-methylglucamine, and procaine.
[0050] Pharmaceutically acceptable acid addition salts include inorganic or organic acid salts. Suitable acid salts include hydrochlorides, formates, acetates, citrates, salicylates, nitrates, and phosphates. Other suitable pharmaceutically acceptable salts are well known to those skilled in the art and include, for example, formic acid, acetic acid, citric acid, oxalic acid, tartaric acid or mandelic acid, hydrochloric acid, hydrobromic acid, sulfuric acid or phosphoric acid; with organic carboxylic acids, sulfonic acids, sulfonic acids or phosphoric acids or N-substituted aminosulfonic acids, such as acetic acid, trifluoroacetic acid (TFA), propionic acid, glycolic acid, succinic acid, maleic acid, hydroxymaleic acid, methylmaleic acid, fumaric acid, malic acid, tartaric acid, lactic acid, oxalic acid, gluconic acid, glucuronic acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, salicylic acid, 4-aminosalicylic acid, 2- Salts of phenoxybenzoic acid, 2-acetoxybenzoic acid, pamoic acid, nicotinic acid or isonicotinic acid; and salts with amino acids, such as the 20 alpha amino acids involved in protein synthesis in nature, such as glutamic acid or aspartic acid, and with phenylacetic acid, methanesulfonic acid, ethanesulfonic acid, 2-hydroxyethanesulfonic acid, ethane 1,2-disulfonic acid, benzenesulfonic acid, 4-methylbenzenesulfonic acid, naphthalene 2-sulfonic acid, naphthalene 1,5-disulfonic acid, 2-phosphoglyceric acid or 3-phosphoglyceric acid, glucose 6-phosphate, N-cyclohexylaminosulfonic acid (for the formation of cyclamates), or with other acidic organic compounds, such as ascorbic acid.
[0051] Other features and advantages of the present invention will be set forth in the description which follows, and in part will be apparent from the description, or may be learned by practice of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS
[0052] The present invention will be further described below with reference to the accompanying drawings and embodiments, wherein:
[0053] Figure 1 This is a diagram showing the difference in abundance of intestinal flora between the Control group and the TAM group of mice in Example 2 of the present invention;
[0054] Figure 2 This is a graph showing the results of detecting the contents of different types of bile acids in feces of mice in the Control group and the TAM group in Example 3 of the present invention;
[0055] in:
[0056] A: The ratio of primary bile acid to secondary bile acid in feces of mice in the Control group and TAM group after oral gavage for 4 weeks;
[0057] B: The ratio of free bile acid to conjugated bile acid in feces of mice in the Control group and TAM group after oral gavage for 4 weeks;
[0058] C: Levels of total bile acid in feces of mice in the Control group and TAM group after oral gavage for 4 weeks;
[0059] D: Composition of primary bile acids and secondary bile acids in feces of mice in the Control group and TAM group after oral gavage for 4 weeks;
[0060] E: The composition of free bile acid and conjugated bile acid in feces of mice in the Control group and TAM group after oral gavage for 4 weeks;
[0061] F: The ratio of primary bile acid to secondary bile acid in feces of mice in the Control group and TAM group after oral gavage for 8 weeks;
[0062] G: The ratio of free bile acid to conjugated bile acid in feces of mice in the Control group and TAM group after oral gavage for 8 weeks;
[0063] H: Total bile acid levels in feces of mice in the Control group and TAM group after 8 weeks of gavage;
[0064] I: Composition of primary and secondary bile acids in feces of mice in the Control group and TAM group after oral gavage for 8 weeks;
[0065] J: Composition of free bile acid and conjugated bile acid in feces of mice in the Control group and TAM group after oral gavage for 8 weeks;
[0066] K: The ratio of primary bile acid to secondary bile acid in feces of mice in the Control group and TAM group after oral gavage for 16 weeks;
[0067] L: The ratio of free bile acid to conjugated bile acid in feces of mice in the Control group and TAM group after oral gavage for 16 weeks;
[0068] M: total bile acid levels in feces of mice in the Control group and TAM group after oral gavage for 16 weeks;
[0069] N: Composition of primary bile acids and secondary bile acids in feces of mice in the Control group and TAM group after oral gavage for 16 weeks;
[0070] O: Composition of free bile acids and conjugated bile acids in feces of mice in the Control group and TAM group after oral gavage for 16 weeks.
[0071] Figure 3 This is a graph showing the results of detecting the transcription level of target genes in the intestinal liver FXR signal of the Control group and the TAM group of mice in Example 4 of the present invention;
[0072] in:
[0073] A: Relative mRNA expression levels of CYP7A1, CYP8B1, CYP27A1, and CYP7B1 genes in the liver of mice in the Control group and TAM group after oral administration for 4 weeks;
[0074] B: Relative mRNA expression levels of FXR and FGF15 genes in the ileum of mice in the Control group and TAM group after oral administration for 4 weeks;
[0075] C: Relative mRNA expression levels of CYP7A1, CYP8B1, CYP27A1, and CYP7B1 genes in the liver of mice in the Control group and TAM group after oral administration for 8 weeks;
[0076] D: Relative mRNA expression levels of FXR and FGF15 genes in the ileum of mice in the Control group and TAM group after oral administration for 8 weeks;
[0077] E: Relative mRNA expression levels of CYP7A1, CYP8B1, CYP27A1, and CYP7B1 genes in the liver of mice in the Control group and TAM group after oral gavage for 16 weeks;
[0078] F: Relative mRNA expression levels of FXR and FGF15 genes in the ileum of mice in the Control group and TAM group after oral administration for 16 weeks.
[0079] Figure 4 This is a graph showing the effect of OCA on TAM hepatotoxicity in Example 5 of the present invention;
[0080] in:
[0081] A: Effects of OCA on the liver GSH content of mice in the Control group;
[0082] B: Effects of OCA on GSSG content in liver of mice in the Control group;
[0083] C: Effects of OCA on the ratio of GSH / GSSG in the liver of mice in the Control group;
[0084] D: Effects of OCA on serum ALP levels in liver of mice in the Control group;
[0085] E: Effects of OCA on the content of GSH in the liver of mice in the TAM group;
[0086] F: Effects of OCA on GSSG content in liver of mice in TAM group;
[0087] G: Effect of OCA on the ratio of GSH / GSSG in the liver of mice in the TAM group;
[0088] H: Effects of OCA on serum ALP levels in liver of mice in the TAM group;
[0089] I: H&E histopathological staining results of OCA intervention group and vehicle group of mice in Control group and TAM group.
[0090] Figure 5 This is a result diagram showing the effect of OCA of Example 6 of the present invention on TAM-induced intestinal and hepatic FXR signaling disorder;
[0091] in:
[0092] A: Effects of OCA on the relative mRNA expression levels of CYP7A1, CYP8B1, CYP27A1 and CYP7B1 genes in the liver of mice in the Control group;
[0093] B: Effects of OCA on the relative expression levels of FXR and FGF15 mRNA in the ileum of mice in the Control group;
[0094] C: Effects of OCA on the relative mRNA expression levels of CYP7A1, CYP8B1, CYP27A1 and CYP7B1 genes in the liver of mice in the TAM group;
[0095] D: Effects of OCA on the relative mRNA expression levels of FXR and FGF15 genes in the ileum of TAM group mice. DETAILED DESCRIPTION
[0096] The following will be combined with the embodiments to clearly and completely describe the concept of the present invention and the technical effects produced, so as to fully understand the purpose, characteristics and effects of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of them. Based on the embodiments of the present invention, other embodiments obtained by those skilled in the art without creative work are all within the scope of protection of the present invention.
[0097] If the specific conditions are not specified in the specific implementation mode, the conventional conditions or the conditions recommended by the manufacturer are used. If the manufacturer of the reagents or instruments is not specified, they are all conventional products that can be purchased from the market.
[0098] The mice used in the specific implementation were female C57 BL / 6J mice, 6 weeks old, weighing 20±2 g, purchased from Guangdong Weitong Lihua Experimental Animal Technology Co., Ltd., and raised in the SPF barrier environment of the Experimental Animal Center of Shenzhen Institute for Drug Control;
[0099] Tamoxifen (TAM) was purchased from Shanghai MacLean Biochemical Technology Co., Ltd., with the catalog number T832955;
[0100] Obeticholic acid (OCA) was purchased from Shanghai Aladdin Biochemical Technology Co., Ltd. with the catalog number I193491;
[0101] Sodium carboxymethyl cellulose (CMC-Na) was purchased from Shanghai MacLean Biochemical Technology Co., Ltd., with the catalog number C804625;
[0102] Reduced glutathione (GSH) content test kit was purchased from Beijing Solebow Technology Co., Ltd., catalog number BC1175;
[0103] The oxidized glutathione (GSSG) content test kit was purchased from Beijing Solebow Technology Co., Ltd., with the catalog number BC1185;
[0104] Alkaline phosphatase (ALP) assay kit was purchased from Nanjing Jiancheng Bioengineering Institute with the catalog number A059-2-2;
[0105] TRizol reagent was purchased from Thermo Fisher Scientific, catalog number 15596026;
[0106] Ⅱ1st Strand cDNASynthesis SuperMix for qPCR kit, purchased from Yisheng Biotechnology (Shanghai) Co., Ltd., catalog number 11120ES60;
[0107] qPCR SYBR Green Master Mix (High Rox Plus) kit was purchased from Yisheng Biotechnology (Shanghai) Co., Ltd. with the catalog number 11203ES08.
[0108] Example 1
[0109] In this example, a TAM hepatotoxicity mouse model and an OCA intervention mouse model were established.
[0110] 1. Preparation of mouse gavage:
[0111] 1) 0.5wt% CMC-Na solution: Add appropriate amount of ultrapure water to a beaker and heat at 55°C; weigh 1g of CMC-Na and add it to the water in small amounts several times, keep heating and stirring, and continue to add water to 200mL until it becomes a transparent clear liquid with no obvious particles, and temporarily store at 4°C;
[0112] 2) TAM solution (20 mg / mL): Prepare TAM solution at a ratio of 4 mg TAM per 200 μL 0.5 wt% CMC-Na solution, stir until it becomes a milky white liquid with no obvious particles, and temporarily store at 4°C;
[0113] 3) OCA solution (1 mg / mL): Prepare an OCA solution at a ratio of 0.2 mg OCA in 200 μL of 0.5 wt % CMC-Na solution, stir continuously until it becomes a milky white liquid with no obvious particles, and temporarily store at 4°C.
[0114] 2. Establishment of TAM hepatotoxicity mouse model:
[0115] Six-week-old mice were adaptively fed for three weeks, during which mice in different cages were exchanged at will and new and old bedding were mixed to balance the intestinal flora. The mice were randomly divided into two groups according to their body weight, a control group (Control) and a model group (TAM). The control group and the model group were gavaged with the same volume of placebo (0.5wt% CMC-Na solution) and TAM solution (20mg / mL), respectively, and the TAM dosage was controlled at 200mg / kg / d. Continuous gavage was performed, and the weight changes of mice were monitored daily. The mice were killed at the end of the experiment, and biological samples such as serum, liver, intestine and its intestinal contents were obtained for pathological and biochemical tests.
[0116] 3. Establishment of OCA intervention mouse model:
[0117] After 12 weeks of oral gavage treatment, mice in the control group and model group were further randomly divided into vehicle group and OCA intervention group according to their body weight. They were gavaged with the same volume of CMC-Na solution (0.5wt%) and OCA solution (1mg / mL), respectively, and the OCA dosage was controlled to be 10mg / kg / d. The oral gavage was continued for 4 weeks, and the weight changes of mice were monitored daily. The mice were killed at the end of the experiment, and biological samples such as serum, liver, intestine and intestinal contents were obtained for pathological and biochemical tests.
[0118] Example 2
[0119] This example studies the effect of TAM on the intestinal flora of mice.
[0120] In order to investigate the effect of TAM on the intestinal flora of mice, the present example used 16S rRNA sequencing technology to detect the composition of the intestinal flora of the mice in the Control group and the TAM group in Example 1. The abundance difference of the intestinal flora of the two groups of mice is as follows: Figure 1 shown.
[0121] from Figure 1The results of intestinal flora abundance showed that compared with the Control group mice, TAM significantly destroyed the balance of intestinal flora of mice. The abundance of Proteobacteria, Enterobacteriaceae and Escherichia, Verrucomicrobia, Akkermansiaceae and Akkermansia in the intestinal flora of TAM group mice increased significantly, and the levels of Firmicutes, Lachnospiraceae and Lachnospira decreased significantly.
[0122] It can be seen from the experimental results of this example that TAM induced intestinal flora disturbance in mice.
[0123] Example 3
[0124] This example studies the effect of TAM on the fecal bile acid profile of mice.
[0125] In order to investigate the effect of TAM on the bile acid profile of mouse feces, this example performed LC-MS / MS targeted bile acid metabolomics detection on the bile acids in the feces of the Control group and TAM group mice at different dosing periods (4 weeks, 8 weeks and 16 weeks) in Example 1. The detection instrument was SHIMADZU Nexera X2 LC-30AD / AB SCIEX Triple Quad 4500 system, and the chromatographic column was Waters ACQUITY HSS T3 column, 100mm×2.1mm id, 1.8μm. The results of the final detection of the concentration and relative content ratio of primary bile acid (Primary BA) and secondary bile acid (Secondary BA), free bile acid (Deconjugated BA) and conjugated bile acid (Conjugated BA) in the mouse feces are as follows: Figure 2 shown.
[0126] from Figure 2 As shown in Figures D, E, I, J, N, and O, free bile acids and secondary bile acids are the main components of fecal bile acids in both the Control group and the TAM group. Comparing the fecal bile acid spectra of mice at different administration periods, as the TAM administration time increases, the proportion of free bile acids and secondary bile acids in feces shows a trend of gradually decreasing. Figure 2 As shown in Figures A, B, K, and L, the proportions of free bile acids and secondary bile acids in the feces of TAM group mice were lower than those of Control group mice in the same period. Figure 2As can be seen from Figures C, H, and M, the total bile acid level in the feces of mice in the TAM group was also significantly lower than that in the Control group during the same period, indicating that TAM administration reduced the excretion of bile acid through feces.
[0127] From the experimental results of this example, it can be seen that TAM reshaped the fecal bile acid profile of mice.
[0128] Example 4
[0129] This example studies the effect of TAM on intestinal and hepatic FXR signaling.
[0130] In order to investigate the effect of TAM on the intestinal hepatic bile acid axis in mice, this example detected the transcription level of the target gene in the intestinal hepatic FXR signal by real-time PCR experiment.
[0131] Experimental process: Total RNA was extracted from the liver and ileum tissues of mice in the Control group and TAM group at different drug administration periods. Ⅱ1st Strand cDNASynthesis SuperMix for qPCR Kit was used to prepare cDNA by reverse transcription reaction of all total RNA samples. qPCR SYBR Green Master Mix (High Rox Plus) kit was used for PCR amplification to detect the transcriptional levels of liver bile acid synthases, CYP7A1, CYP8B1, CYP27A1, and CYP7B1, as well as FXR and FXR signal activation in the ileum to release fibroblast growth factor 15 (FGF15). The real-time PCR primer sequences of each gene and the reference gene are shown in Table 1 . The experimental results are shown in Figure 3 shown.
[0132] Table 1 Real-time PCR primer sequence information for each detection gene and internal reference gene
[0133]
[0134]
[0135] Depend on Figure 3 Figures A, B, C, D, E, and F show that TAM induces abnormal intestinal and hepatic FXR signaling, resulting in highly active liver BA synthases CYP7A1, CYP8B1, CYP27A1, and CYP7B1, as well as overactivation of ileal FXR signaling. In the early stages of TAM toxicity (4 weeks, e.g. Figure 3As shown in Figures A and B in Figure 2, intestinal and hepatic FXR signaling undergoes a stress-induced transcriptional process, and as TAM treatment time increases (8 and 16 weeks, as shown in Figure 2), ... Figure 2 The above phenomenon can be explained by two reasons: first, proteins are functional executors, and genes need to undergo complex modification and translation processes after transcription to express functional proteins. When a large number of transcription products are consumed by the pathway, the target gene will be in a "normal or low transcription" state. Second, the bile acid profile of mice shows a dynamic change process with the extension of TAM treatment time ( Figure 2 As shown in Figures D, E, I, J, N, and O in the figure, FXR receptors have different affinities for different bile acids, and different bile acid profiles lead to different feedbacks in the enterohepatic FXR signal.
[0136] From the experimental results of this example, it can be seen that the TAM-related bile acid profile characteristics significantly affect the enterohepatic FXR signal, causing enterohepatic FXR signal disorder; and the liver CYP8B1 and CYP7B1 are continuously in a highly transcribed state, indicating that the host has feedback regulation of the abnormal enterohepatic FXR signal caused by TAM, but it still cannot be effectively reversed to a normal state, suggesting that additional measures are needed for auxiliary intervention.
[0137] Example 5
[0138] This example studies the effect of OCA on TAM-induced hepatotoxicity.
[0139] In order to investigate the role of OCA in TAM hepatotoxicity, this example used the vehicle group and OCA intervention group mice obtained by treating the mice in the control group and TAM group in Example 1 to conduct experiments, and performed hematoxylin-eosin (H&E) histopathological staining on the liver of the mice, and performed hepatotoxicity biochemical index detection, specifically: using an alkaline phosphatase kit (ALP) assay kit to detect the ALP level in the serum of the mice, and using a reduced glutathione (GSH) content test kit and an oxidized glutathione (GSSG) content test kit to detect the liver's ability to resist oxidative stress. The experimental results are as follows: Figure 4 shown.
[0140] For the mice in the Control group, Figure 4 As shown in Figure I (the scale bar in the figure is 300 nm), the pathological results showed that OCA had no toxic effects on liver cells; Figure 4 The biochemical test results in Figure D show that OCA does not affect the serum ALP level of mice; Figure 4As shown in Figures A, B, and C, OCA did not affect the content of GSH in the liver, but significantly reduced the content of GSSG, thereby increasing the GSH / GSSG content ratio in the liver of mice. Figure 4 As shown in Figure I, the pathological results showed that OCA could alleviate the damage caused by TAM to mouse liver cells and significantly reduce liver cell edema; Figure 4 The biochemical test results of Figure H in Figure 2 showed that OCA could significantly reduce the serum ALP level of mice; Figure 4 As shown in Figures F and G, OCA also significantly reduced the content of GSSG in the liver and increased the ratio of GSH / GSSG, indicating that OCA can enhance the antioxidant stress resistance of the damaged liver.
[0141] It can be seen from the experimental results of this example that OCA can significantly reduce the hepatotoxicity of TAM.
[0142] Example 6
[0143] This example studies the effect of OCA on TAM-induced enterohepatic FXR signaling disorder.
[0144] In order to further investigate the role of OCA in TAM-induced intestinal liver FXR signaling disorder, this example used the OCA intervention group and vehicle group mice treated with OCA in Example 1 to conduct experiments, and the transcription level of the target gene in the intestinal liver FXR signaling was detected by real-time PCR experiment. The experimental method was the same as that in Example 4, and the results were shown in Figure 4. Figure 5 shown.
[0145] For the mice in the Control group, Figure 5 As shown in Figures A and B, OCA mainly exerted a significant effect on ileal FXR signaling, significantly reducing the transcription levels of FXR and FGF15, but had no significant effect on hepatic bile acid synthase. Figure 5 As shown in Figures C and D, OCA can antagonize ileal FXR signaling, inhibit the high transcription state of hepatic bile acid synthase, and reverse the abnormal intestinal and hepatic FXR signaling induced by TAM.
[0146] From the experimental results of this example, it can be seen that OCA can improve the intestinal hepatic FXR signaling disorder induced by TAM.
[0147] In summary, the present invention found that obeticholic acid can restore the damage of TAM hepatotoxicity to hepatocytes and reduce hepatocyte edema; OCA can also significantly reduce the GSSG content of damaged liver, increase the liver GSH / GSSG content ratio, and enhance the anti-oxidative stress ability of damaged liver; and OCA can also significantly reduce serum ALP levels, thereby reducing TAM hepatotoxicity; in addition, obeticholic acid treatment can improve the abnormal conduction of enterohepatic FXR signals caused by tamoxifen, and reverse the abnormal conduction of enterohepatic FXR signals induced by TAM. Therefore, the present invention verifies the therapeutic potential of obeticholic acid in TAM hepatotoxicity, has the potential to become a therapeutic strategy for the clinical management of TAM hepatotoxicity, and expands the indications of obeticholic acid.
[0148] The above is a detailed description of the embodiments of the present invention, but the present invention is not limited to the above embodiments. Various changes can be made within the knowledge of ordinary technicians in the relevant technical field without departing from the purpose of the present invention. In addition, the embodiments of the present invention and the features in the embodiments can be combined with each other without conflict.
Claims
1. Use of obeticholic acid and / or its pharmaceutically acceptable salts in the preparation of a medicament for treating tamoxifen hepatotoxicity.
2. The use according to claim 1, characterized in that: The tamoxifen hepatotoxicity includes drug-induced liver injury caused by the use of tamoxifen endocrine therapy for breast cancer.
3. The use according to claim 1, characterized in that: The functions of the drug specifically include at least one of reducing hepatocyte edema, enhancing the liver's ability to resist oxidative stress, reducing serum ALP levels, and improving tamoxifen-induced enterohepatic FXR signaling disorders.
4. The use according to claim 3, characterized in that: The enhancing the liver's anti-oxidative stress ability includes reducing the GSSG content in the liver and / or increasing the GSH / GSSG content ratio in the liver.
5. The use according to claim 3, characterized in that: The improvement of tamoxifen-induced enterohepatic FXR signaling disorder includes reducing the expression of hepatic bile acid synthase.
6. The use according to claim 5, characterized in that: The liver bile acid synthase includes at least one of CYP7A1, CYP8B1, CYP27A1 or CYP7B1.
7. The use according to claim 1, characterized in that: The dosage of obeticholic acid and / or its pharmaceutically acceptable salt in the medicine is 5 to 40 mg / kg / d.
8. The use according to claim 1, characterized in that: The dosage form of the medicine is tablet, capsule, granule, pill, oral liquid, dry suspension, dry extract or injection.
9. A drug for combined treatment of breast cancer and tamoxifen hepatotoxicity, characterized in that: The active ingredients of the drug include tamoxifen and obeticholic acid.
10. The drug according to claim 9, characterized in that The dosage of tamoxifen in the medicine is 100 to 300 mg / kg / d, and the dosage of obeticholic acid in the medicine is 5 to 40 mg / kg / d.
Citation Information
Patent Citations
Crystalline forms of obeticholic acid
CN110831602A
